ELXM.F Stock Overview
Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nova Eye Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.19 |
| 52 Week Low | AU$0.10 |
| Beta | 0.79 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -68.75% |
| 5 Year Change | -83.33% |
| Change since IPO | -86.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELXM.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.9% |
| 1Y | n/a | 13.7% | 22.6% |
Return vs Industry: Insufficient data to determine how ELXM.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ELXM.F performed against the US Market.
Price Volatility
| ELXM.F volatility | |
|---|---|
| ELXM.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ELXM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ELXM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | n/a | Tom Spurling | www.nova-eye.com |
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally.
Nova Eye Medical Limited Fundamentals Summary
| ELXM.F fundamental statistics | |
|---|---|
| Market cap | US$30.74m |
| Earnings (TTM) | -US$7.42m |
| Revenue (TTM) | US$10.25m |
3.0x
P/S Ratio-4.1x
P/E RatioIs ELXM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELXM.F income statement (TTM) | |
|---|---|
| Revenue | AU$15.23m |
| Cost of Revenue | AU$3.06m |
| Gross Profit | AU$12.17m |
| Other Expenses | AU$23.19m |
| Earnings | -AU$11.02m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 79.94% |
| Net Profit Margin | -72.40% |
| Debt/Equity Ratio | 7.3% |
How did ELXM.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/23 06:43 |
| End of Day Share Price | 2023/04/25 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nova Eye Medical Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Michael Youlden | MST Financial Services Pty Limited |
| Robin Morgan | Taylor Collison Limited |